IL132281A0 - Modified tnf alpha molecules dna encoding such modified tnf alpha molecules and vaccines comprising such modified tnf alpha molecules and dna - Google Patents

Modified tnf alpha molecules dna encoding such modified tnf alpha molecules and vaccines comprising such modified tnf alpha molecules and dna

Info

Publication number
IL132281A0
IL132281A0 IL13228198A IL13228198A IL132281A0 IL 132281 A0 IL132281 A0 IL 132281A0 IL 13228198 A IL13228198 A IL 13228198A IL 13228198 A IL13228198 A IL 13228198A IL 132281 A0 IL132281 A0 IL 132281A0
Authority
IL
Israel
Prior art keywords
tnf alpha
modified tnf
alpha molecules
dna
vaccines
Prior art date
Application number
IL13228198A
Other languages
English (en)
Original Assignee
Ferring Farma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Farma Lab filed Critical Ferring Farma Lab
Publication of IL132281A0 publication Critical patent/IL132281A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/14Lymphokine; related peptides
    • Y10S930/144Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13228198A 1997-04-15 1998-04-15 Modified tnf alpha molecules dna encoding such modified tnf alpha molecules and vaccines comprising such modified tnf alpha molecules and dna IL132281A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (1)

Publication Number Publication Date
IL132281A0 true IL132281A0 (en) 2001-03-19

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13228198A IL132281A0 (en) 1997-04-15 1998-04-15 Modified tnf alpha molecules dna encoding such modified tnf alpha molecules and vaccines comprising such modified tnf alpha molecules and dna

Country Status (30)

Country Link
US (1) US7118750B1 (zh)
EP (1) EP0975668B1 (zh)
JP (1) JP2001521386A (zh)
KR (1) KR100522289B1 (zh)
CN (1) CN1178955C (zh)
AR (1) AR012427A1 (zh)
AT (1) ATE326481T1 (zh)
AU (1) AU743400B2 (zh)
BR (1) BR9811462A (zh)
CA (1) CA2289476A1 (zh)
CZ (1) CZ9903657A3 (zh)
DE (1) DE69834556T2 (zh)
DK (1) DK0975668T3 (zh)
EE (1) EE9900461A (zh)
ES (1) ES2264569T3 (zh)
HK (1) HK1022918A1 (zh)
HR (1) HRP980203B1 (zh)
HU (1) HUP0001930A3 (zh)
IL (1) IL132281A0 (zh)
NO (1) NO995002L (zh)
NZ (1) NZ337955A (zh)
PL (1) PL194221B1 (zh)
RU (1) RU2241715C2 (zh)
SI (1) SI0975668T1 (zh)
SK (1) SK285639B6 (zh)
TR (1) TR199902562T2 (zh)
TW (1) TW510921B (zh)
UA (1) UA72440C2 (zh)
WO (1) WO1998046642A1 (zh)
ZA (1) ZA983148B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ATE488250T1 (de) * 1999-03-02 2010-12-15 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
JP2003535905A (ja) * 2000-06-21 2003-12-02 フェリング ベスローテン フェンノートシャップ 可溶化されたタンパク質ワクチン
EP1485122A2 (en) * 2002-03-11 2004-12-15 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
BRPI0407058A (pt) * 2003-02-01 2006-01-17 Neuralab Ltd Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
CN1960744A (zh) 2004-02-27 2007-05-09 瓦克斯咨询公司 肽IL1β和TNFα以及应用其治疗的方法
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
MX2010003114A (es) * 2007-09-25 2010-06-23 Intervet Int Bv Vacuna para tratamiento de osteoartritis.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
BR112012010698A2 (pt) 2009-11-05 2016-11-29 Uab Research Foundation método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012076668A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性A−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
AU2016256876B2 (en) 2015-05-05 2021-02-04 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位,含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107362T1 (de) * 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
NO995002L (no) 1999-12-15
TW510921B (en) 2002-11-21
TR199902562T2 (xx) 2000-02-21
RU2241715C2 (ru) 2004-12-10
KR100522289B1 (ko) 2005-10-19
EP0975668B1 (en) 2006-05-17
WO1998046642A1 (en) 1998-10-22
EE9900461A (et) 2000-06-15
PL194221B1 (pl) 2007-05-31
HUP0001930A3 (en) 2001-10-29
US7118750B1 (en) 2006-10-10
HRP980203B1 (en) 2003-04-30
AU7030398A (en) 1998-11-11
UA72440C2 (en) 2005-03-15
CA2289476A1 (en) 1998-10-22
CN1252809A (zh) 2000-05-10
ZA983148B (en) 1999-10-15
DE69834556T2 (de) 2007-05-10
CZ9903657A3 (cs) 2001-09-12
CN1178955C (zh) 2004-12-08
SK285639B6 (sk) 2007-05-03
NZ337955A (en) 2000-09-29
NO995002D0 (no) 1999-10-14
DE69834556D1 (de) 2006-06-22
PL336295A1 (en) 2000-06-19
JP2001521386A (ja) 2001-11-06
KR20010006416A (ko) 2001-01-26
HUP0001930A2 (hu) 2000-09-28
ES2264569T3 (es) 2007-01-01
DK0975668T3 (da) 2006-09-25
EP0975668A1 (en) 2000-02-02
ATE326481T1 (de) 2006-06-15
SI0975668T1 (sl) 2007-02-28
AR012427A1 (es) 2000-10-18
AU743400B2 (en) 2002-01-24
SK140999A3 (en) 2000-06-12
BR9811462A (pt) 2000-09-12
HRP980203A2 (en) 1998-12-31
HK1022918A1 (en) 2000-08-25

Similar Documents

Publication Publication Date Title
IL132281A0 (en) Modified tnf alpha molecules dna encoding such modified tnf alpha molecules and vaccines comprising such modified tnf alpha molecules and dna
IL134480A0 (en) Kay - an immune system protein and dna sequences encoding the same
IL136216A0 (en) Polypeptides and nucleic acids encoding the same
HUP0104296A3 (en) Cross-linked hyaluronic acids, uses thereof and biological substances containing them
HUP9902571A3 (en) Variants of thymidine kinase, related nucleic acids sequences and their use in genic therapy
EP0948651A4 (en) RECOMBINANT N-SMASES AND NUCLEIC ACIDS ENCODING THEM
AU6667998A (en) Nucleic acids encoding caspase-8h and caspase-8i
HUP0102302A3 (en) Gene coding for heliomicine and use thereof
AU5874798A (en) Vaccination methods and molecules
HUT77108A (hu) DNS-szekvenciák és alkalmazásuk
HU9700676D0 (en) Anti-fas recombinante antibodies and dna coding thereof
IL107880A (en) Galectin-8 and galectin-8-like proteins and DNA molecules coding therefor
HUP0103784A2 (hu) MUC-1-et kódoló DNS molekulák és ezek alkalmazása tumorellenes vakcinálásban
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
EP1044216A4 (en) DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEINS, nNR7 AND nNR7-1
AU8772598A (en) Dna encoding the human synapsin iii gene and uses thereof
DE69532881D1 (de) Ecdn - protein und dafuer kodeierende dna
IL144287A0 (en) Dna molecules encoding human clax proteins and their soluble fusion proteins
GB9824357D0 (en) Protein and DNA coding therefor
EP1007540A4 (en) DNA MOLECULES ENCODE PROTEINS OF THE HUMAN CORE RECEPTOR
EP1012160A4 (en) TANGO-72 AND TANGO-77 NUCLEIC ACID AND POLYPEPTID MOLECULES
IL124567A0 (en) Hemorrhagic enteritis virus dna sequences proteins encoded thereby and various uses thereof
IL136477A0 (en) Human thyroid protein zsig45 and dna encoding same
GB9828022D0 (en) Enzyme and DNA sequence encoding same
EP0857732A4 (en) HUMAN PROTEIN ANALOGUE TO PEC-60 AND THE DNA THAT ENCODES IT